Host Cofactors and Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost upon Disassembly
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The HIV-1 capsid is involved in all infectious steps from reverse transcription to integration site selection, and is the target of multiple host cell and pharmacologic ligands. However, structural studies have been limited to capsid monomers (CA), and the mechanistic basis for how these ligands influence infection is not well understood. Here we show that a multi-subunit interface formed exclusively within CA hexamers mediates binding to linear epitopes within cellular cofactors NUP153 and CPSF6, and is competed for by the antiretroviral compounds PF74 and BI-2. Each ligand is anchored via a shared phenylalanine-glycine (FG) motif to a pocket within the N-terminal domain of one monomer, and all but BI-2 also make essential interactions across the N-terminal domain: C-terminal domain (NTD:CTD) interface to a second monomer. Dissociation of hexamer into CA monomers prevents high affinity interaction with CPSF6 and PF74, and abolishes binding to NUP153. The second interface is conformationally dynamic, but binding of NUP153 or CPSF6 peptides is accommodated by only one conformation. NUP153 and CPSF6 have overlapping binding sites, but each makes unique CA interactions that, when mutated selectively, perturb cofactor dependency. These results reveal that multiple ligands share an overlapping interface in HIV-1 capsid that is lost upon viral disassembly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 CPSF6 and NUP153 interact with distinct sets of CA residues within the hexamer interface. A molecular surface representation of the CPSF6 and NUP153 binding site in hexameric capsid is shown in gray. The interface is formed between two neighbouring monomers and is shown in a similar orientation to Figure 3. The CPSF6 (A) and NUP153 (B) peptides in the different complexed structures are shown in yellow and pink respectively. The binding ‘footprint’ of each ligand is shown in red for CPSF6 and yellow for NUP153. The footprint was calculated using PISA [44] and is defined as residues containing atoms that become desolvated upon binding (i.e. are within 1.4 Å of the ligand).](https://figures.cochat.ai/paper-figures/327adc62c78b4401a48bf088e2d7894f/host-cofactors-and-pharmacologic-ligands-share-an-essential-interface-in-hiv-1-figure-4.jpg)


![Figure 7 HIV-1 CA hexamer complexes with pharmacologic ligands BI-2 and PF74. Two monomers from hexameric structures complexed with BI-2 (A) and PF74 (B) are shown in a close-up view of the binding site, with one monomer in gray and a second monomer in teal. BI-2 is shown in orange and PF74 in green. Important CA interacting residues are shown as sticks and putative hydrogen bonds indicated by dashed lines. Ligplots [45] are shown for BI-2 (C) and PF74 (D) in which a ball-and-stick representation of the ligand is shown together with CA residues that contribute a hydrogen bond. Other interacting CA residues are indicated with a red-dashed semi-circle. Circled areas indicate interacting CA residues that are shared between both structures. (E) Superposition of the BI-2:hexamer complex (BI-2 in orange) with the previously solved BI-1:CA-NTD complex [28] (BI-1 in blue). The secondary structure of the superposed monomers from each structure is shown in gray, while capsid side-chains from only the hexamer complex are depicted. The adjacent monomer in the hexamer complex is shown in teal. (F) Superposition of the PF74:hexamer complex (PF74 in green) with the previously solved PF74:CA-NTD complex [27] (PF74 in slate). The capsids are colored as in (E).](https://figures.cochat.ai/paper-figures/7cf5249be85940bd90f08d2edaf59d69/host-cofactors-and-pharmacologic-ligands-share-an-essential-interface-in-hiv-1-figure-7.jpg)

![Figure 9 Inhibition of HIV-1 infection by BI-2, PF74 and PF74 derivatives. (A) Titration of PF74 or indicated derivatives onto HeLa cells infected with VSV-G pseudotyped GFP-encoding HIV-1 vector. For each titration, infectivity is normalised to the level in the absence of inhibitor (100%). (B) Correlation between the IC90 values derived from (A) and the Kd values for purified hexameric capsid as calculated by ITC (Figure 8). The values are highly correlative with a Pearson correlation coefficient of 0.9928 and a P-value of 0.0007. (C) Titration of PF74 or BI-2 onto cells infected with VSV-G pseudotyped GFP-encoding HIV-1 vectors, normalized as in (A). (D) Data from (C) but with infectivity plotted against drug concentration divided by affinity to hexamer as calculated by ITC. (E) Titres of VSV-G pseudotyped GFP-encoding HIV-1 vectors 48 h post-infection and levels of reverse transcription (RT) 4 h post-infection under conditions of PF74 inhibition. For both measures, data are normalized to the values obtained in the absence of inhibitor. (F) Data from (E), except plotted against the calculated level of CA occupancy by PF74. The occupancy was calculated assuming that there are 1500 free sites per capsid and that number of free sites = 1500(1−([PF74]/Kd[PF74])) (G) Infectivity and reverse transcription in cells infected in the presence of PF74 (wash) or when removed after four hours (wash out). Reverse transcription was then measured after a further 4 h, while infectivity was determined 48 h post-infection. (H) Levels of reverse transcription 4 h post-infection of HeLa cells in the presence of PF74 and its derivatives at 20× IC9o drug concentrations.](https://figures.cochat.ai/paper-figures/fc100b1cf62b406592ce6fd8f22ac865/host-cofactors-and-pharmacologic-ligands-share-an-essential-interface-in-hiv-1-figure-9.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cleavage and polyadenylation specificity factor 6 (CPSF6), which is a component of the cellular pre-mRNA cleavage and polyadenylation machinery79, binds the same region of capsid as Nup153 (REF.78,80).”
From Structure and function of retroviral integrase (2022) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984 · cited 1×
“The footprint was calculated using PISA [44] and is defined as residues containing atoms that become desolvated upon binding (i.”
MethodLigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
Laskowski, R. A., & Swindells, M. B. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200227u · Cited by 6,471 · cited 1×
“Ligplots [45] are shown for BI-2 (C) and PF74 (D) in which a ball-and-stick representation of the ligand is shown together with CA residues that contribute a hydrogen bond.”
BackgroundIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Identification of host proteins required for HIV infection through a functional genomic screen
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1152725 · Cited by 1,449
Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 Replication
König, R., Zhou, Y., Elleder, D., Diamond, T. L., Bonamy, G. M. C., Irelan, J. T., Chiang, C.-Y., Tu, B. P., De Jesus, P. D., Lilley, C. E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.032 · Cited by 960
Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., et al. (2002) · Nature · doi:10.1038/nature01188 · Cited by 889
Specific incorporation of cyclophilin A into HIV-1 virions
Franke, E. K., Yuan, H. E. H., & Luban, J. (1994) · Nature · doi:10.1038/372359a0 · Cited by 745
HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704 · cited 2×
“proteins TNPO3, NUP153, NUP358 [4,5,6], and LEDGF [7].”
X-Ray Structures of the Hexameric Building Block of the HIV Capsid
Pornillos, O., Ganser-Pornillos, B. K., Kelly, B. N., Hua, Y., Whitby, F. G., Stout, C. D., Sundquist, W. I., Hill, C. P., & Yeager, M. (2009) · Cell · doi:10.1016/j.cell.2009.04.063 · Cited by 523 · cited 4×
“One potential explanation for this is that all three structures were solved using monomeric CA NTD, whereas a fully assembled HIV-1 capsid is comprised exclusively of multimeric CA, predominately hexamers, containing both NTD-NTD and NTD-CTD interfaces [31].”
BackgroundInfluential
Cited by
Items 201–290 of 290
Taylor, I. A., & Fassati, A. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad076 · Cited by 9
“…from adjacent capsid subunits that is the binding site for Sec24C ( Rebensburg et al., 2021 ) , CPSF6 ( Bhattacharya et al., 2014 ) , and Nup153 ( Price et al., 2014 ) , as well as capsid-binding drug molecules, and ( iv) the electronegative inter-hexamer junction at the 3-fold…”
BackgroundResultInfluentialThe HIV-1 Capsid: More than Just a Delivery Package
James, L. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14741-9_4 · Cited by 9
Self-citationCyclophilin A Regulates Tripartite Motif 5 Alpha Restriction of HIV-1
Wang, T., Becker, D., Twizerimana, A. P., Luedde, T., Gohlke, H., & Münk, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020495 · Cited by 6
“A NUP153 share the same binding site between the highly resistant virus with five CA mutations (Q67H, K70R, H87P, T107N, and L111I) was discovered during the first characterization of PF74 [237]. capsid NTD and the CTD (Figure 8) [63,201,232].”
InfluentialAn Update on Antiretroviral Therapy
Menéndez‐Arias, L., Martín-Alonso, S., & Frutos-Beltrán, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-0267-2_2 · Cited by 9
Defining the HIV Capsid Binding Site of Nucleoporin 153
Li, S., Patel, J. S., Yang, J., Crabtree, A., Rubenstein, B. M., Lund-Andersen, P. K., Ytreberg, F. M., & Rowley, P. A. (2022) · mSphere · doi:10.1128/msphere.00310-22 · Cited by 9
“This discrepancy between modeling and 235 empirical data is likely due to the water-mediated interaction of T1416 with CA residues 236 R173 and E63 (21).”
BackgroundMethodInfluentialRapid HIV-1 Capsid Interaction Screening Using Fluorescence Fluctuation Spectroscopy
Lau, D., Walsh, J. C., Dickson, C. F., Tuckwell, A., Stear, J. H., Hunter, D. J. B., Bhumkar, A., Shah, V. B., Turville, S. G., Sierecki, E., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04250 · Cited by 4
Self-citationLong, M., Cantrelle, F., Robert, X., Boll, E., Sierra, N., Gouet, P., Hanoulle, X., Álvarez, G., & Guillon, C. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00228 · Cited by 8
Cell Type-Dependent Escape of Capsid Inhibitors by Simian Immunodeficiency Virus SIVcpz
Twizerimana, A. P., Scheck, R., Becker, D., Zhang, Z., Wammers, M., Avelar, L. A. A., Pflieger, M., Häussinger, D., Kurz, T., Gohlke, H., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01338-20 · Cited by 7
“with two inhibitory phases flanking a plateau phase (19, 29, 33, 60).”
BackgroundThe secrets of the stability of the HIV-1 capsid
Obr, M., & Kräusslich, H. (2018) · eLife · doi:10.7554/elife.38895 · Cited by 6
HIV-1 is more dependent on the K182 capsid residue than HIV-2 for interactions with CPSF6
Saito, A., Ode, H., Nohata, K., Ohmori, H., Nakayama, E. E., Iwatani, Y., & Shioda, T. (2019) · Virology · doi:10.1016/j.virol.2019.04.012 · Cited by 6
Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499
Wang, C., Huang, H., Valera, L., Parcella, K. E., Iwuagwu, C. I., McAuliffe, B., Falk, P. J., O’Boyle, D. R., Rose, R. E., Padilla, R., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00309-25 · Cited by 5
Viral interference of nucleocytoplasmic transport
Chien, C., Mobbs, G. W., Ehrenkranz, J. R. L., & Hoelz, A. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110815 · Cited by 9
CP-MAS and Solution NMR Studies of Allosteric Communication in CA-assemblies of HIV-1
Nicastro, G., Lucci, M., Oregioni, A., Kelly, G. P., Frenkiel, T. A., & Taylor, I. A. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167691 · Cited by 5
Zhang, D., Xu, X., Zhou, R., & Fu, Z. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1270258 · Cited by 5
“Our newly discovered compound SA or SB, also inhibited the CA hexamer/ CPSF6 peptide and the CA hexamer/NUP153 peptide interaction indicating that it is binding in the pocket formed by two neighboring CA subunits.”
BackgroundInfluentialSpearman, P. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00047-2 · Cited by 12
Comparative analysis of retroviral Gag-host cell interactions: focus on the nuclear interactome
Lambert, G. S., Rice, B. L., Maldonado, R. J. K., Chang, J., & Parent, L. J. (2024) · Retrovirology · doi:10.1186/s12977-024-00645-y · Cited by 5
Viral Protein Dimerization Quality Control: A Design Strategy for a Potential Viral Inhibitor
Du, S., Liu, X., Hu, X., & Zhan, P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01540 · Cited by 5
Identifying a nuclear passport for HIV
Zuliani‐Alvarez, L., & Towers, G. J. (2019) · eLife · doi:10.7554/elife.45580 · Cited by 5
A DNA-origami nuclear pore mimic reveals nuclear entry mechanisms of HIV-1 capsidPreprint
Shen, Q., Xu, C., Jang, S., Xiong, Q., Devarkar, S. C., Tian, T., Bedwell, G. J., Tripler, T. N., Hu, Y., Yuan, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.10.245522 · Cited by 6
“…tri-hexamer interface (EE212/213AA, E75A), the di-hexamer interface (EE180/181AA), the FG pocket (N74D, Q67A, N57D), the CypA-binding loop (P90A, G89V), and the hexamer central pore (R18D) (Bhattacharya et al., 2014; Dick et al., 2018; Price et al., 2014; Schaller et al., 2011; Smaga et al., 2019).”
BackgroundInfluentialSelf-citationStructural basis for HIV-1 capsid adaption to a deficiency in IP6 packaging
Zhu, Y., Kleinpeter, A. B., Rey, J. S., Shen, J., Shen, Y., Xu, J., Hardenbrook, N. J., Chen, L., Lucic, A., Perilla, J. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63363-9 · Cited by 5
Halambage, U. D., Wong, J. P., Melancon, B. J., Lindsley, C. W., & Aiken, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-15 · Cited by 4
“BI-2 is another capsid-targeting HIV-1 inhibitor that interacts with the same PF74 binding pocket but with lower affinity (16).”
BackgroundSelf-citationZhang, W., Mendonça, L., & Mansky, L. M. (2018) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-10-8456-0_8 · Cited by 5
Sahani, R. L., Akther, T., Cilento, M. E., Castaner, A. E., Zhang, H., Kirby, K. A., Xie, J., Sarafianos, S. G., & Wang, Z. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00292a · Cited by 4
Gruenke, P. R., Mayer, M. D., Aneja, R., Schulze, W. J., Song, Z., Burke, D. H., Heng, X., & Lange, M. J. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00708 · Cited by 4
Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis
Akther, T., McFadden, W. M., Zhang, H., Kirby, K. A., Tedbury, P. R., & Wang, Z. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03305-0 · Cited by 3
“…important pocket located in the interface between CA C-terminus (CA1 CTD ) and the N-terminus of the adjacent CA (CA2 NTD ), is targeted by host factors, including cytoplasmic protein Sec24C [2], nuclear pore protein NUP153 [3], and nuclear protein CPSF6 [4], using a conserved FG-motif [5, 6].”
HIV capsids: orchestrators of innate immune evasion, pathogenesis and pandemicity
Morling, K. L., ElGhazaly, M., Milne, R. S. B., & Towers, G. J. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002057 · Cited by 8
“…experimental capsid inhibitor PF74 and the Gilead first- in-class ultra-potent capsid targeting drug lenacapavir (LEN), which contain phenyl (PF74) and difluorobenzyl (LEN) moieties that super-impose with the FG motif in the crystal structures of the host cofactors [93, 97, 98, 116, 237, 238].”
InfluentialCellular Factors That Regulate Retrovirus Uncoating and Reverse Transcription
Goff, S. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811185-7.00002-9 · Cited by 3
Mx Oligomer: A Novel Capsid Pattern Sensor?
Kong, J., Ma, M., He, S., & Qin, X. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0004 · Cited by 3
Berry, F., Khalfi, P., Maillot, F., Seigneres, P., Ahmed, S. S., & Nunzio, F. D. (2018) · médecine/sciences · doi:10.1051/medsci/20183406006 · Cited by 4
The HIV-1 capsid core is an opportunistic nuclear import receptorPreprint
Xue, G., Yu, H. J., Goh, S. L., Gres, A. T., Guney, M. H., Sarafianos, S. G., Luban, J., & KewalRamani, V. N. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.02.470925 · Cited by 3
Karyopherin mimicry explains how the HIV capsid penetrates nuclear poresPreprint
Dickson, C. F., Hertel, S., Ruan, J., Ariotti, N., Tuckwell, A., Li, N., Al-Izzi, S. C., Sierecki, E., Gambin, Y., Morris, R. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.23.534032 · Cited by 3
Self-citationDecoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with nuclear specklesPreprint
Tomasini, C., Cuche, C., Ay, S., Collard, M., Cui, B., Rashid, M., Bhattacharjee, S., Tello-Rubio, B., Buchrieser, J., Luchsinger, C., et al. (2024) · eLife · doi:10.7554/elife.103725 · Cited by 9
“…as targets for various nucleoporins, especially the ones carrying FG repeats, facilitating the translocation of the capsid through the nuclear pore complex (NPC) ( Buffone et al., 2018 ; Di Nunzio, 2013 ; Di Nunzio et al., 2012 ; Lelek et al., 2015 ; Matreyek et al., 2013 ; Price et al., 2014 ).”
IP6, PF74 affect HIV-1 capsid stability through modulation of hexamer-hexamer tilt angle preference
Garza, C. M., Holcomb, M., Santos‐Martins, D., Torbett, B. E., & Forli, S. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.12.016 · Cited by 3
Álvarez, G., van Pul, L., Robert, X., Artía, Z., van Nuenen, A. C., Long, M., Sierra, N., Porcal, W., Kootstra, N. A., & Guillon, C. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00581-7 · Cited by 2
Decoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with nuclear speckles
Tomasini, C., Cuche, C., Ay, S., Collard, M., Cui, B., Rashid, M., Bhattacharjee, S., Tello-Rubio, B., Buchrieser, J., Luchsinger, C., et al. (2026) · eLife · doi:10.7554/elife.103725.3 · Cited by 4
Artía, Z., Guillon, C., Robert, X., Granzella, M., Segovia, A. C., Truong, H. H., Álvarez, G., Corvo, I., & Randall, L. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151572 · Cited by 2
Lang, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00111k · Cited by 2
The Human T-cell Leukemia Virus capsid protein is a potential drug target
Yu, R., Phalora, P. K., Li, N., Böcking, T., & Jacques, D. A. (2025) · Nature Communications · doi:10.1038/s41467-025-65899-2 · Cited by 3
“HIV uses this site to engage with multiple host proteins, including Sec24C 34 , CPSF6 35 , and the phenylalanine-glycine (FG) repeat domains of the nuclear pore complex 22,35 .”
InfluentialSelf-citationRetroviral restriction: nature's own solution
Jones, C. E., & McKnight, Á. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000322 · Cited by 3
“Evidence continues to mount that the capsid needs to remain intact as it makes its way through the cytoplasm to the nucleus [65,66].”
BackgroundNuclear Pore Complexes, Genome Organization and HIV-1 Infection
Nunzio, F. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-71614-5_8 · Cited by 4
Ruddell, S., Sugrue, E., Memarzadeh, S., Hellam, L. M., Wilson, S. J., & France, D. J. (2021) · Molecules · doi:10.3390/molecules26133919 · Cited by 2
The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1
Saito, A., Sultana, T., Ode, H., Nohata, K., Samune, Y., Nakayama, E. E., Iwatani, Y., & Shioda, T. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0250 · Cited by 2
An anticipated optimization approach to macromolecular crystallizationPreprint
Gorrec, F. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/620328 · Cited by 1
“…samples has been fully described elsewhere: ESCRT-II complex (‘ESCRT-II’), 115 kDa, 7 mg ml−1 (Teo et al., 2004); Human p53 DNA-binding domain Y220C mutant (‘QMp53y220c’), residues 94-312, 49 kDa, 6.0 mg/ml (Joerger et al., 2004); HIV capsid (‘HIV-1-CA’), 25 kDa, 32 mg ml−1 (Price et al., 2014).”
InfluentialChemical Stabilization of the HIV-1 Capsid Results in Efficient HIV-1 Reverse Transcription in vitroPreprint
Jennings, J., Shi, J., Varadarajan, J., Jamieson, P. J., & Aiken, C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.17.302315 · Cited by 2
Self-citationBarnett, M., Sun, L., Xu, S., Liu, X., Zhan, P., & Goldstone, D. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.16.553511 · Cited by 2
Decoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with the nuclear specklePreprint
Tomasini, C., Cuche, C., Ay, S., Collard, M., Cui, B., Rashid, M., Bhattacharjee, S., Buchrieser, J., Luchsinger, C., Bertelli, C., et al. (2024) · eLife · doi:10.7554/elife.103725.1 · Cited by 2
Characterization of antiviral compounds using Bio-Layer InterferometryPreprint
Lorson, Z. C., McFadden, W. M., Neilsen, G., Castaner, A. E., Slack, R. L., Kirby, K. A., & Sarafianos, S. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.24.662752 · Cited by 2
“However, unlike LEN, PF74 is highly susceptible to degradation by cellular enzymes, but is commonly used as a benchmark or control for experiments investigating CA targeting compounds 14, 29–31 .”
Santiago-Jiménez, J. C., Ramírez-Damaso, G., Caballero, F., & Castillo-Alvarado, F. D. L. (2026) · MRS Advances · doi:10.1557/s43580-026-01619-2 · Cited by 1
HIV-1 uncoating location dictates sites of integration
Burdick, R. C., Patro, S. C., Bare, E. K., Siddiqui, R., Delviks‐Frankenberry, K. A., Nikolaitchik, O. A., Hughes, S. H., Wu, X., Hu, W.-S., & Pathak, V. K. (2026) · Nature Communications · doi:10.1038/s41467-026-71679-3 · Cited by 2
Zhang, X., Sun, L., Walsham, L., Ma, Y., Ding, D., Wang, M. S., Zhao, F., Zhang, J., Wang, Z., Xu, S., et al. (2026) · MedComm · doi:10.1002/mco2.70746 · Cited by 1
“It competes with multiple host factors, including CPSF6, NUP153, and Sec24C, which share a similar binding site (Figure 1C ) [ 29, 36, 37 ].”
[Progress in the study of HIV capsid structure and drug discovery].
Li, J., & Wang, W. (2015) · PubMed · Cited by 1
HIV-1 Capsid as a Target for Antiviral Therapy
Zhang, Z., & Zhang, F. (2016) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000536 · Cited by 1
“(2) The reported cocrystal structure shows PF74 targets the same binding pocket in the assembled CA as those of CPSF6 and NUP153 [46].”
BackgroundNucleoporins in Retroviral Replication
Monette, A., & Mouland, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811185-7.00003-0 · Cited by 1
Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Import in Non-Dividing CellsPreprint
Opp, S., Martínez‐López, A., Fricke, T., Buffone, C., Severgnini, M., Cifola, I., Frabetti, S., Skorupka, K. A., Zadrozny, K. K., Ganser‐Pornillos, B. K., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155897 · Cited by 2
Structural basis for HIV-1 capsid adaption to rescue IP6-packaging deficiencyPreprint
Zhu, Y., Kleinpeter, A. B., Rey, J. S., Shen, J., Shen, Y., Xu, J., Hardenbrook, N. J., Chen, L., Lucic, A., Perilla, J. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.09.637297 · Cited by 1
Kirby, K. A., McFadden, W. M., Wang, L., Du, H., Zhang, H., Castaner, A. E., Lorson, Z. C., Nafisi, A., Selyutina, A., Luchsinger, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.30.696960 · Cited by 1
Kanja, M., Cappy, P., Blanco-Rodriguez, G., Levy, N., Oladosu, O., Schmidt, S., Gasser, R., Rossolillo, P., Moog, C., Ruff, M., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3208264
Building Complexity: Making and Breaking Synthetic Subunits of the HIV Capsid
James, L. C., & Böcking, T. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.07.011
Self-citationTravis, C., Nakamura, T., Amano, M., Takamune, N., Matsuoka, M., & Nakata, H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.18.444758
Recognition of HIV-1 Capsid Licenses Innate Immune Response to Viral InfectionPreprint
Yoh, S. M., Mamede, J. I., Lau, D., Ahn, N., Sánchez-Aparicio, M. T., Temple, J. E., Tuckwell, A., Fuchs, N. V., Cianci, G. C., Riva, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.10.472699
Informatically-informed biochemical characterization of aptamer-protein complexes
Gruenke, P. R. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/91663
Gruenke, P. R., Mayer, M. D., Aneja, R., Song, Z., Burke, D. H., Heng, X., & Lange, M. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.11.571135
Cyclophilin A Facilitates HIV-1 DNA IntegrationPreprint
Padron, A., Dwivedi, R., Chakraborty, R., Prakash, P., Kim, K., Shi, J., Ahn, J., Pandhare, J., Luban, J., Aiken, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.15.599180
“PF74 binds to a pocket at the NTD–CTD inter-subunit interface of CA and exhibits a concentration-dependent anti-viral activity [33, 95-98].”
BackgroundSelf-citationLi, S., Lund-Andersen, P. K., Wang, S., Ytreberg, F. M., Naik, M. T., Patel, J. S., & Rowley, P. A. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002104
“However, in NUP153, one FG motif has been shown to bind with high affinity to a hydrophobic pocket formed between two CA monomers in the context of a hexamer and bind with lower affinity to CA monomers [17, 37].”
InfluentialHIV-1 capsid found guilty of breaking and entering
Dharan, A., & Campbell, E. M. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02071-y
The intersection of viral mimicry and nuclear entry
Dickson, C. F., Phalora, P. K., & Jacques, D. A. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.07.002 · Cited by 1
Self-citationTranslocation of HIV capsid core through the Nuclear Pore Complex by affinity gradientPreprint
Melčák, I., Slack, R. L., Lorson, Z. C., Castaner, A. E., Ambrus, K., Winkjer, J. S., Kirby, K. A., Dick, R. A., & Sarafianos, S. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.02.680059
Decoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with the nuclear specklePreprint
Tomasini, C., Cuche, C., Ay, S., Collard, M., Cui, B., Rashid, M., Bhattacharjee, S., Tello-Rubio, B., Buchrieser, J., Luchsinger, C., et al. (2025) · eLife · doi:10.7554/elife.103725.2
Álvarez, G., van Pul, L., Robert, X., Artía, Z., van Nuenen, A. C., Long, M., Sierra, N., Porcal, W., Kootstra, N. A., & Guillon, C. (2022) · Figshare · doi:10.6084/m9.figshare.20175620
Cabrera-Rodríguez, R., Pons-Grífols, A., Pernas, M., Casado, C., Trujillo‐González, R., Lorenzo-Sánchez, I., Reyes-Castañeda, I., Trinité, B., Blanco, J., & Valenzuela-Fernández, A. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02762-x
“Likewise, HIV-1 CA engages ligands like Nup153, CPSF6 [149], and the antiviral compounds PF-3,450,074 (PF74) [150] and BI-2 [151], via overlapping CA-hexamer interface with a shared FG motif, and when CA-disassembled monomers lose this binding, reveals mechanistic impacts on infection [149].”
McFadden, W. M., Kirby, K. A., Lorson, Z. C., Wang, L., Highland, C. M., Harvey, S. R., Brancato, S. G., Castaner, A. E., Du, H., Wysocki, V. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.19.712970
Molecular architecture and fate of HIV-1 pre-integration
Blanco-Rodriguez, G. (2019) · theses.fr (ABES) · doi:10.70675/8643077az5a0fz4f20zbabazb129e8359d96
Rôle des partenaires de CTIP2 dans la latence post-intégrative du VIH-1 : importance de la voie SUMO
Assche, J. V. (2022) · theses.fr (ABES) · doi:10.70675/3cb6a549ze973z487dz98f4z6fbf5991098c
Identification of specific phylogenetic properties of HIV-1 M and O integrases
Toccafondi, E. (2022) · theses.fr (ABES) · doi:10.70675/2facab6ezc20az472dz8350z9fb6e718e1d4 · Cited by 1
Hou, Z., & Zhang, P. (2026) · Annual Review of Virology · doi:10.1146/annurev-virology-100424-125355
Ranaweera, A., Andino-Moncada, J. R., Dillon, S. E., Singh, S. P., Stagg, S. M., Engelman, A., Aiken, C., & Francis, A. C. (2026) · iScience · doi:10.1016/j.isci.2026.116378 · Cited by 1
“Small molecule inhibitors, including PF74 13 and the clinically approved drug lenacapavir (LEN), 13–15 block HIV-1 infection by binding the assembled capsid structure 13,15–17 and perturbing its functions.”
Self-citationMelčák, I., Slack, R. L., Lorson, Z. C., Castaner, A. E., Ambrus, K., Winkjer, J. S., Kirby, K. A., Dick, R. A., & Sarafianos, S. G. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534919123 · Cited by 2
“Other host factors, including the primarily nuclear protein cleavage - and - polyadenylation - specificity factor 6 (CPSF6), also bind to the FG pocket of the core via the FG motif at the interface between two CA subunits (44–47).”
InfluentialHIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances
Mahdi, M., Lakatos, B., Mótyán, J. A., Hoffka, G., & Tőzsér, J. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014361
“This binding site of LEN can be occupied by other molecules, for example, by small-molecule inhibitor PF-3450074 [71], as well as by host proteins, such as cellular RNA processing factor CPSF6 [72], nuclear import/pore protein NUP153 [73], or protein transport protein Sec24C [74].”
Jiang, X., Yu, R., Foley, N., Xue, X., Dai, J., Wang, M., Nie, Z., Chen, C., Clercq, E. D., Pannecouque, C. C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01058
Self-citationCapsid stabilization reprograms the nuclear fate of the HIV genome
Mourer, T., Harastani, M., Cuche, C., Lopez, J. I. P., Tornambè, S., Tachon, S., Corre, G., Maristany, M. J., Tinévez, J.-Y., Gazi, A. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef9469
Percipalle, M., Thader, A., Hodirnau, V.-V., Dick, R. A., & Schur, F. K. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.16.759032
“The retroviral CA-NTD contributes stabilizing contacts in both immature and mature lattices, but also occupies a more exposed position and participates in interactions with cellular factors, as demonstrated for HIV-1 36,39–41 .”
Capillary physics links HIV capsid geometry to nuclear pore translocation
Brown, A. W., Al-Izzi, S. C., Parker, J. L., Hertel, S., Jacques, D. A., Kusumaatmaja, H., & Morris, R. G. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2605059123
Self-citationBindingDB Entry 50015611: An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q21z48bw
BindingDB Entry 50022399: Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023.
BindingDB (2025) · UC San Diego · doi:10.7270/q23201k8
Singh, P. (2026) · Harvard Dataverse · doi:10.7910/dvn/udt6uc
Processed HIV-1 integration site datasets from Jurkat cells with capsid mutants
Singh, P. (2026) · Harvard Dataverse · doi:10.7910/dvn/xrkmnr
Metadata
- Authors
- Price, A. J., Jacques, D. A., McEwan, W. A., Fletcher, A. J., Essig, S., Chin, J. W., Halambage, U. D., Aiken, C., & James, L. C.
- Affiliations
- MRC Laboratory of Molecular Biology (GB)
- Vanderbilt University (US)
- Corresponding author
- James, Leo C.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-30
- Volume
- 10
- Issue
- 10
- Pages
- e1004459
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC4214760
- OpenAlex
- W2170915201
- Cited by
- 284
- References
- 45
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 21 · 2021: 41 · 2020: 31 · 2019: 28 · 2018: 24 · 2017: 8 · 2016: 19 · 2015: 20 · 2014: 2
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- UTS ePRESS (University of Technology Sydney) (submittedVersion)
- Funders
- National Institutes of Health
- Medical Research Council (U105181010)
- National Health and Medical Research Council (1036521)
- National Institute of Allergy and Infectious Diseases (R01AI089401)
- FP7 Ideas: European Research Council (281627)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 capsid, host cofactors, Nup153, CPSF6, capsid disassembly, conformational dynamics, antiretroviral drugs
- MeSH terms
- Binding Sites, Capsid, Humans, Indoles, Ligands, Models, Molecular, Models, Structural, Mutation, Phenylalanine, Polycyclic Compounds, Protein Binding, Virion, HIV-1, HIV Infections, Protein Structure, Tertiary, Anti-HIV Agents, Nuclear Pore Complex Proteins, Capsid Proteins, mRNA Cleavage and Polyadenylation Factors, Reverse Transcription, Polymerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.